Model for End-Stage Liver Disease (MELD) Score Among Patients Qualified For Lung Transplantation With End-Stage Lung Diseases With Particular Consideration of Median Pulmonary Artery Pressure

被引:1
|
作者
Stacel, Tomasz [1 ]
Necki, Miroslaw [1 ]
Latos, Magdalena [1 ,2 ]
Urlik, Maciej [1 ]
Antonczyk, Remigiusz [1 ,2 ]
Kos, Aleksandra [1 ,2 ]
Zawadzki, Fryderyk [1 ,2 ]
Wajda-Pokrontka, Marta [1 ,2 ]
Przybylowski, Piotr [1 ,3 ]
Zembala, Marian [1 ,2 ]
Ochman, Marek [1 ,2 ]
机构
[1] Silesian Ctr Heart Dis, Zabrze, Poland
[2] Med Univ Silesia, Dept Cardiac Vasc & Endovasc Surg & Transplantol, Katowice, Poland
[3] Jagiellonian Univ, Chair Gen Surg 1, Med Coll, Krakow, Poland
关键词
SERUM SODIUM; COMPLICATIONS; MORTALITY; OUTCOMES;
D O I
10.1016/j.transproceed.2020.03.043
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Model for End-Stage Liver Disease (MELD) score is used to assess the severity of chronic liver disease. It is implemented in transplantology in the process of qualification for urgent liver transplant. The aim of our study was to assess the liver function of patients qualified for lung transplant using MELD score, taking under consideration mean pulmonary artery pressure as an important risk factor of death. Methods. The study group consisted of 123 patients qualified for lung transplant in Silesian Center for Heart Diseases between 2004 and 2017. Data relevant for MELD score calculations and medial pulmonary artery pressure were acquired from medical records. Results. The average MELD score among patients qualified for lung transplant was 8.24 points, and mean pulmonary pressure (mPAP) was 35.02 mm Hg. Patients with idiopathic pulmonary artery hypertension acquired the highest MELD and highest mPAP results (13.1 points and 57.7 mm Hg, respectively). Patients with idiopathic pulmonary fibrosis presented higher mean MELD-Na score among those with pulmonary arterial hypertension than those without pulmonary arterial hypertension (36.59 mm Hg; 7.74 points vs 18 mm Hg; 6.5 points). There is strong positive correlation between MELD-Na and mPAP among patients who underwent lung transplant because of idiopathic pulmonary fibrosis. Conclusions. This is the first study in the worldwide literature assessing MELD-Na as a predictor of survival among patients qualified for lung transplant and those who already are recipients. Further studies regarding this issue are required as authors will explore this issue in the future.
引用
收藏
页码:2128 / 2132
页数:5
相关论文
共 50 条
  • [41] Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis
    Sheng, Qin-Song
    Lang, Ren
    He, Qiang
    Yang, Yong-Jiu
    Zhao, De-Fang
    Chen, Da-Zhi
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2009, 8 (01) : 46 - 49
  • [42] Living Donor Liver Transplantation for Adults With High Model for End-stage Liver Disease Score: The US Experience
    Rosenthal, Benjamin E.
    Abt, Peter L.
    Schaubel, Douglas E.
    Reddy, K. Rajender
    Bittermann, Therese
    TRANSPLANTATION, 2024, 108 (03) : 713 - 723
  • [43] Application of Hepatic Venous Pressure Gradient to Predict Prognosis in Cirrhotic Patients with a Low Model for End-stage Liver Disease Score
    Chang, Young
    Suk, Ki Tae
    Jeong, Soung Won
    Yoo, Jeong-Ju
    Kim, Sang Gyune
    Kim, Young Seok
    Lee, Sae Hwan
    Kim, Hong Soo
    Kang, Seong Hee
    Baik, Soon Koo
    Kim, Dong Joon
    Kim, Moon Young
    Jang, Jae Young
    DIAGNOSTICS, 2020, 10 (10)
  • [44] Commentary: Mind MELD complete: Can the model for end-stage liver disease (MELD) score predict risk in isolated tricuspid surgery?
    DeRoo, Scott C.
    Aldea, Gabriel S.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 166 (05) : 1442 - 1443
  • [45] Prognostic value of the modified model for end-stage liver disease (MELD) score including albumin in acute heart failure
    Shengen Liao
    Xinyi Lu
    Iokfai Cheang
    Xu Zhu
    Ting Yin
    Wenming Yao
    Haifeng Zhang
    Xinli Li
    BMC Cardiovascular Disorders, 21
  • [46] Lung Congestion as a Risk Factor in End-Stage Renal Disease
    Zoccali, Carmine
    Tripepi, Rocco
    Torino, Claudia
    Bellantoni, Marianna
    Tripepi, Giovanni
    Mallamaci, Francesca
    BLOOD PURIFICATION, 2013, 36 (3-4) : 184 - 191
  • [47] Survival benefit of lung transplantation compared with medical management and pulmonary rehabilitation for patients with end-stage COPD
    Timofte, Irina
    Wijesinha, Marniker
    Vesselinov, Roumen
    Kim, June
    Reed, Robert
    Sanchez, Pablo G.
    Ladikos, Nicholas
    Pham, Si
    Kon, Zachary
    Rajagopal, Keshava
    Scharf, Steven M.
    Wise, Robert
    Sternberg, Alice L.
    Kaczorowski, David
    Griffith, Bartley
    Terrin, Michael
    Iacono, Aldo
    ERJ OPEN RESEARCH, 2020, 6 (02)
  • [48] Defining a Liver Transplant Benefit Threshold for the Model for End-Stage Liver Disease-Sodium Score
    Beal, Eliza W.
    Akateh, Clifford
    Tumin, Dmitry
    Bagante, Fabio
    Black, Sylvester M.
    Washburn, Kenneth
    Azouley, Daniel
    Pawlik, Timothy M.
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2020, 18 (04) : 491 - 497
  • [49] The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites
    Kim, Jun Jae
    Kim, Jeong Han
    Koo, Ja Kyung
    Choi, Yun Jung
    Ko, Soon Young
    Choe, Won Hyeok
    Kwon, So Young
    CLINICAL AND MOLECULAR HEPATOLOGY, 2014, 20 (01) : 47 - 55
  • [50] The Model for End-stage Liver Disease 3.0 is not superior to the Model for End-stage Liver Disease-Na in predicting survival: A retrospective cohort study
    Duan, Fangfang
    Liu, Chen
    Zhai, Hang
    Quan, Min
    Cheng, Jun
    Yang, Song
    HEPATOLOGY COMMUNICATIONS, 2023, 7 (10)